gennova-biopharmaceuticals-limitedgennova-biopharmaceuticals-limited
  • Home
    • Home
    • Contact Us
    • Careers
  • About Us
    • About Us
    • Company Profile
    • Our Values
    • Board of Directors
    • Our Strengths
    • PDL
    • Our Collaborations
  • Media
    • Media
    • News Coverage
    • Gallery
    • Employee Moments
  • Products
    • Products
    • Elaxim®
    • GEMCOVAC®-OM
    • Hamsyl®
    • Hamsyl® Junior
    • PEGEX®
    • TENECTASE®
    • Vintor®
    • Xgrast®
  • Publications
  • Abhyudaya
  • Transforming Healthcare
    • Transforming Healthcare
    • Global Health Initiative
      • Global Health Initiative
      • PHT
Gennova Logo Gennova Logo
  • Home
    • Home
    • Contact Us
    • Careers
  • About Us
    • About Us
    • Company Profile
    • Our Values
    • Board of Directors
    • Our Strengths
    • PDL
    • Our Collaborations
  • Media
    • Media
    • News Coverage
    • Gallery
    • Employee Moments
  • Products
    • Products
    • Elaxim®
    • GEMCOVAC®-OM
    • Hamsyl®
    • Hamsyl® Junior
    • PEGEX®
    • TENECTASE®
    • Vintor®
    • Xgrast®
  • Publications
  • Abhyudaya
  • Transforming Healthcare
    • Transforming Healthcare
    • Global Health Initiative
      • Global Health Initiative
      • PHT
 
Research Articles

Robust antibody and CD8+ T-cell responses induced by P. falciparum CSP adsorbed to cationic liposomal adjuvant CAF09 confer sterilizing immunity against experimental rodent malaria infection.

  • admin
  • April 9, 2020

NPJ Vaccines. 2017;2. pii: 10. doi: 10.1038/s41541-017-0011-y. Epub 2017 Apr 10. PubMed PMID: 28936360; PubMed Central PMCID: PMC5603302.

https://www.ncbi.nlm.nih.gov/pubmed/?term=28936360

Share
Gennova Logo

About Gennova

Board of Directors
Research Collaborations
Corporate Governance
Internships
Careers
Press Kit
Contact Us

Products

Elaxim®
GEMCOVAC®-OM
Hamsyl®
Hamsyl® Junior

PEGEX®
TENECTASE®
Vintor®
Xgrast®

©2006-2025 Gennova Biopharmaceuticals Limited. All rights reserved.